Passa P, Giraud S
Service d'Endocrinologie-Diabétologie, Hôpital Saint-Louis, Paris, France.
Diabete Metab. 1993 Dec;19(5 Suppl):523-7.
In insulin-dependent and non insulin-dependent diabetic patients, the treatment of a modest increase in blood pressure values has been proved effective in reducing the incidence and in improving the evolution of various locations of diabetic angiopathy. This beneficial effect is associated with a cost which can be evaluated by the analysis of IMS and DOREMA data. In France, the evolution of the sales of antihypertensive agents in diabetic patients increased from 117 MF in 1980 to 784 MF in 1991. This dramatic increase is mainly related to the prescription of new antihypertensive agents: calcium antagonists and ACE inhibitors. From 1980 to 1991, the evolution of antihypertensive agent's sales was more important in diabetic patients than in the general population. In 1991, the total cost of antidiabetic treatment: insulin, antidiabetic oral agents and strips for capillary blood glucose monitoring was about 1,100 MF, quite similar to the cost of antihypertensive and hypolipidemic agents used in the same patients.
在胰岛素依赖型和非胰岛素依赖型糖尿病患者中,已证明对血压值适度升高进行治疗,在降低糖尿病血管病变各部位的发病率及改善其发展进程方面是有效的。这种有益效果伴随着一定成本,可通过分析IMS和DOREMA数据来评估。在法国,糖尿病患者中抗高血压药物的销售额从1980年的1.17亿法郎增至1991年的7.84亿法郎。这一显著增长主要与新型抗高血压药物(钙拮抗剂和血管紧张素转换酶抑制剂)的处方有关。从1980年到1991年,抗高血压药物销售额的增长在糖尿病患者中比在普通人群中更为显著。1991年,糖尿病治疗的总成本(胰岛素、口服抗糖尿病药物和毛细血管血糖监测试纸)约为11亿法郎,与同一批患者使用的抗高血压和降血脂药物的成本相当。